A new study set to be published in the Journal of Virology concluded that a mass infant vaccination campaign for Hepatitis B that began in 1992 caused the virus to more than double its breakout mutations rate by 2005. Medical Xpress reports, “These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.”
Hepatitis B can cause abdominal and joint pain, jaundice, nausea and vomiting, fatigue and in severe cases, it can lead to death. While vaccination campaigns are widely credited by the medical community in protecting inoculated children from the disease, breakout viral mutations would essentially render these protections useless.
These findings seem to corroborate those published in the journal Hepatology earlier this year which showed that protections for a significant portion of adolescents who receive a full set of Hep B shots actually wear off over time. Depending on the brand, 3-4 doses of Hep B vaccine are required during infancy to be considered ‘effective’ at building immunity against the disease.
Researcher Tao Bian of Chapel Hill says that the vaccine remains quite effective, but that because escape mutants are likely to increase, public health officials need to track the rise of escape mutants, in order to know when it becomes time to consider new vaccination strategies. (source)
As more children all over the world are vaccinated for Hepatitis B, the vaccine will continue to create more and more viral mutations over time. Eventually this will cause the initial vaccine to stop working anyway. Concurrently, because that vaccine will be useless, the creation of more new vaccines will be required to fix the problem the first vaccine created.
In other words, the neverending spiral of mutations caused by the creation of the Hepatitis B vaccine will require a neverending supply of new vaccines.
When asked for comment on this new study’s findings, the pharmaceutical industry screamed, “Woo-hoo! What a great business model!”